Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › MOMENTUM

MOMENTUM

Pemvidutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Pemvidutide
Population
obesity
Phase
2
Participants
391
Duration
48 weeks
Registry
NCT05295875

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
pemvidutide 2.4 mgobesity48391——−15.6 % vs −2.2 %
estimand not specified
—19.6 vs 6.2—51.5 vs 11.327.8 vs 3.1—−4.6 vs +3.5press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (5)
  • pemvidutide 2.4 mg · ae_dc · Summary of Safety and Tolerability table: Placebo (N=97) | 1
    All AEs leading to discontinuation N (%) | 6 (6.2%) | 5 (5.1%) | 19 (19.2%) | 19 (19.6%)
  • pemvidutide 2.4 mg · nausea · Summary of Safety and Tolerability table: Placebo (N=97) | 1
    Nausea N (%) | 11 (11.3%) | 25 (25.5%) | 59 (59.6%) | 50 (51.5%)
  • pemvidutide 2.4 mg · vomiting · Summary of Safety and Tolerability table: Placebo (N=97) | 1
    Vomiting N (%) | 3 (3.1%) | 6 (6.1%) | 27 (27.3%) | 27 (27.8%)
  • pemvidutide 2.4 mg · sbp · Blood Pressure and Heart Rate table
    Blood Pressure and Heart Rate | Placebo (N=97) | 1.2 mg (N=98) | 1.8 mg (N=99) | 2.4 mg (N=97) Δ Systolic BP mm Hg, LSM (SE) | +3.5 (2.3) | -2.3 (2.2) | -1.6 (2.2) | -4.6 (2.3)
  • pemvidutide 2.4 mg · weight_unsp · Summary of Efficacy Findings
    Primary Endpoint: Body weight | Placebo (N=97) | 1.2 mg (N=98) | 1.8 mg (N=99) | 2.4 mg (N=97) Δ Body weight, all subjects, %, LSM (SE) [1 MMRM] | -2.2 (1.4) | -10.3 (1.4)*** | -11.2 (1.4)*** | -15.6 (1.4)***

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: MOMENTUM. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/momentum/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.